{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:03:52Z","timestamp":1772838232674,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.vaccine.2024.126183","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:32:00Z","timestamp":1722454320000},"page":"126183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China"],"prefix":"10.1016","volume":"42","author":[{"given":"Shicheng","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinxing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12 Suppl 2","key":"10.1016\/j.vaccine.2024.126183_bb0010","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1093\/infdis\/jiaa622","article-title":"Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication","volume":"Sep 30;224","author":"Modlin","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126183_bb0015","first-page":"161","article-title":"Global eradication of poliomyelitis by the year 2000","volume":"63","author":"World Health Organization","year":"1988","journal-title":"Week Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2024.126183_bb0020","series-title":"Chapter 18: Poliomyelitis. Epidemiology and prevention of vaccine-preventable diseases, a.k.a. \u201cthe pink book\u201d. Centers for Disease Control and Prevention","author":"Estivariz","year":"2021"},{"key":"10.1016\/j.vaccine.2024.126183_bb0030","author":"South-east Asia region declared polio-free"},{"key":"10.1016\/j.vaccine.2024.126183_bb0035","author":"WHO news"},{"key":"10.1016\/j.vaccine.2024.126183_bb0040","author":"WHO news"},{"key":"10.1016\/j.vaccine.2024.126183_bb0050","series-title":"Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial. J INFECT DIS","author":"Hu","year":"2019"},{"key":"10.1016\/j.vaccine.2024.126183_bb0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: a progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2024.126183_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2021.01.027","article-title":"Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population","author":"Jiang","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126183_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial","author":"Chu","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126183_bb0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4155\/ppa.12.70","article-title":"Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains","volume":"1","author":"Hamidi","year":"2012","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.vaccine.2024.126183_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2024.126183_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.03.012","article-title":"Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study","author":"Chu","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126183_bb0090","author":"Hu","year":"2019"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126183_bb0095","article-title":"Immune persistence following primary immunization and the immunogenicity and safety of a booster dose of a multidose Sabin strain-based inactivated polio vaccine in infants aged 18 months","volume":"12","author":"Feng","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126183_bb0100","series-title":"Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial. Vaccines (Basel)","author":"Zheng","year":"2022"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126183_bb0105","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1080\/21645515.2021.2010428","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial","volume":"17","author":"Liu","year":"2021","journal-title":"Hum Vacc Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126183_bb0110","doi-asserted-by":"crossref","first-page":"2161789","DOI":"10.1080\/21645515.2022.2161789","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis a vaccine: a phase 4, single-center, randomized, controlled trial","volume":"19","author":"Sun","year":"2023","journal-title":"HUM VACC IMMUNOTHER"},{"key":"10.1016\/j.vaccine.2024.126183_bb0115","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/infdis\/jiz129","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and group a meningococcal polysaccharide vaccine: a phase 4, open-label, single-center, randomized, noninferiority trial[J]","volume":"220","author":"Zhang","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126183_bb0120","series-title":"Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial. Front Immunol","author":"Sun","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126183_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2023.10.006","article-title":"Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China","author":"Xu","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"82","key":"10.1016\/j.vaccine.2024.126183_bb0130","article-title":"Polio returns to the USA: an epidemiological alert","volume":"Sep 6","author":"Rai","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"23","key":"10.1016\/j.vaccine.2024.126183_bb0135","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.vaccine.2021.04.032","article-title":"Pertussis vaccine effectiveness and duration of protection - a systematic review and metaanalysis","volume":"39","author":"Wilkinson","year":"2021","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2024.126183_bb0140","doi-asserted-by":"crossref","first-page":"1055677","DOI":"10.3389\/fimmu.2022.1055677","article-title":"Comparing the pertussis antibody levels of healthy children immunized with four doses of DTap-IPV\/Hib (Pentaxim) combination vaccine and DTaP vaccine in Quzhou, China","volume":"Jan 6","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126183_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2007.11.008","article-title":"Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial","volume":"26","author":"Jiang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126183_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2012.04.038","article-title":"Interchangeability and tolerability of two inactivated hepatitis a vaccines in Chinese children","volume":"30","author":"Zhang","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T11:00:46Z","timestamp":1724065246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24008466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0264410X24008466"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126183","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126183"}}